FDA Approves Genentech Drug as a Weapon for Fighting Breast Cancer
Feb 23rd, 2008 by Axel
(NewsVisual, powered by IntellectSpace) — The San Francisco-based biotechnology company Genentech Inc (NYSE: DNA) announced on Friday that the U.S. Food and Drug Administration (FDA) granted accelerated approval for one of its drugs to be used metastatic breast cancer. The FDA’s approval means that the company’s drug Avastin can be used in combination along with another drug named Paclitaxel. “There is no cure for metastatic breast cancer; so it is important to control the disease as early a
Blogged with Flock
